Xylem (XYL) opened Q1 2026 with revenue of US$2.1 billion and basic EPS of US$0.79, alongside trailing twelve month revenue of US$9.1 billion and basic EPS of US$4.03 that reflect how the business has been performing through the full cycle. Over the past year, revenue has moved from US$8.6 billion to US$9.1 billion on a trailing basis, while basic EPS has shifted from US$3.67 to US$4.03. This gives you a clear read on how the top and bottom line have tracked into this quarter. With a net profit margin of 10.8% over the last 12 months and earnings growth of 8.3%, the latest numbers give investors a view on how current margins are feeding into the broader growth story.

See our full analysis for Xylem.

With the headline figures on the table, the next step is to set these results against the main narratives around Xylem to see which stories still hold up and where the data starts to push back.

Margins Hold Steady Around 10.8%

• Over the last 12 months, Xylem converted US$9.1b of revenue into US$981 million of net income, which works out to a 10.8% net margin compared with 10.5% a year earlier.
• Consensus narrative suggests that operational simplification and acquisitions are supporting better profitability, and the recent numbers both support and challenge that view:
  • On one hand, the move from a 10.5% to a 10.8% net margin over the past year lines up with the idea that cost efforts and mix shifts are helping profitability.
  • On the other hand, trailing earnings growth of 8.3% sits below the 5 year average of 24.5% per year, so the pace that consensus expects from efficiency gains is not reflected in the most recent growth rate.

Quarterly EPS Bumps Around Within Upward LTM Trend

• Q1 2026 basic EPS was US$0.79 compared with US$0.70 in Q1 2025, while trailing twelve month EPS moved from US$3.73 in Q1 2025 to US$4.03 in Q1 2026, showing how the rolling earnings base has shifted even as individual quarters vary.
• Bulls argue that investments in digital solutions and acquisitions can push earnings higher over time, and recent EPS trends partly back that up but also show some bumpiness:
  • The LTM EPS increase from US$3.73 to US$4.03 sits in the same direction as the bullish view that earnings can keep building as digital and services revenue grows.
  • At the same time, quarterly EPS has ranged from US$0.70 to US$1.38 over the last five reported quarters, so the 8.3% trailing earnings growth is much lower than the bullish narrative that leans on a 24.5% five year growth pace.

On top of these earnings swings, bullish investors often focus on how water infrastructure trends and higher margin digital offerings might shape the story over several years rather than quarter to quarter moves. That is where the more optimistic narrative starts to differ from the recent 8.3% growth pace. 🐂 Xylem Bull Case

Valuation Sits Between Peers And Industry

• At a share price of US$117.91, Xylem trades on a trailing P/E of 29.2x, which is below the 35.3x peer average, above the 27.6x US Machinery industry average, and below a DCF fair value of US$156.56, while analysts’ average price target sits at US$152.82.
• Bears highlight that growth forecasts are slower than the wider US market, and the current multiples and targets leave room to question how much is already reflected in the price:
  • Forecast earnings growth of about 12% per year and revenue growth of roughly 4.1% per year both sit below broader US market expectations, which is the core of the cautious view.
  • Yet the combination of a 1.46% dividend yield, a share price below both the US$152.82 analyst target and the US$156.56 DCF fair value, and a P/E below the peer average means the current setup is not purely aligned with a bearish stance.

Skeptical investors who point to slower forecast growth and industry level P/E comparisons may still want to weigh those concerns against the valuation gap to DCF fair value and analyst targets before leaning too hard into the cautious narrative. 🐻 Xylem Bear Case

Next Steps

To see how these results tie into long-term growth, risks, and valuation, check out the full range of community narratives for Xylem on Simply Wall St. Add the company to your watchlist or portfolio so you'll be alerted when the story evolves.

If the mix of bullish and cautious points here feels finely balanced, now is a good time to look at the details yourself and pressure test the story. To see what optimism in the market is built on, start with the 5 key rewards.

See What Else Is Out There

While Xylem’s margins are steady, the 8.3% trailing earnings growth and slower forecast growth than the broader US market show that momentum is not especially strong.

If you want ideas where valuations and growth expectations may line up more clearly with upside potential, now is a good time to scan the 53 high quality undervalued stocks and compare alternatives side by side.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.